Search

SWG Grant-funded projects, 2023

In November and December of 2022, SWGs were invited to develop project ideas and apply for a 2023 SWG Grant. ApplicationsWe received nine different applications from six SWGs.

Publications

Management of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel
Gökbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding AK, Foà R, Giebel S, Hoelzer D, Hunault M, Marks DI, Martinelli G, Ottmann O, Rijneveld…

Chairs and Members

The EHA SWG commenced in 2020, but initial work was delayed due to the COVID-19 pandemic. We therefore started in 2021, in preparation for a (successful) SWG meeting in 2022.

Advocacy priorities

The European Union works on countless pieces of legislation and policies that affect the health ecosystem. Some are relevant to most medical disciplines, including hematology—such as the legislation on health data or pharmaceuticals.

Faculty information

We are honored that you have agreed to be part of the faculty for the EHA-HKSH Hematology Tutorial on Lymphoid Malignancies, to be held on April 5-6, 2025 in Hong Kong.

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Jun 12 2015 Posted in Press releases

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.